Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov;25(6):1133-1135.
doi: 10.1007/s10120-022-01343-4. Epub 2022 Sep 24.

Reply to: Letter to editor on the article "Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy"

Joe Yeong  1   2 , Chong Boon Teo  3 , Ryan Yong Kiat Tay  3 , Benjamin Kye Jyn Tan  3 , Yiong Huak Chan  4 , Elizabeth C Smyth  5 , Raghav Sundar  6   7   8   9   10
Affiliations
Comment

Reply to: Letter to editor on the article "Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy"

Joe Yeong et al. Gastric Cancer. 2022 Nov.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Yeong J, Lum HYJ, Teo CB, Tan BKJ, Chan YH, Tay RYK, et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer. 2022;25(4):741–50. https://doi.org/10.1007/s10120-022-01301-0 . - DOI - PubMed - PMC
    1. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. https://doi.org/10.1016/S0140-6736(21)00797-2 . - DOI - PubMed - PMC
    1. Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–33. https://doi.org/10.1016/S0140-6736(18)31257-1 . - DOI - PubMed
    1. Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov. 2022;12(3):670–91. https://doi.org/10.1158/2159-8290.CD-21-0683 . - DOI - PubMed
    1. Sundar R, Liu DH, Hutchins GG, Slaney HL, Silva AN, Oosting J, et al. Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. Gut. 2021;70(10):1823–32. https://doi.org/10.1136/gutjnl-2020-320805 . - DOI - PubMed

LinkOut - more resources